Valuation : Healios K.K.

Market Cap 39.83B 249M 215M 202M 184M 346M 23.61B 348M 2.39B 929M 12.01B 934M 914M P/E 2026 *
-7.88x
P/E 2027 * -12.8x
Enterprise Value 39.57B 247M 213M 201M 183M 344M 23.46B 345M 2.37B 923M 11.93B 928M 908M EV / Sales 2026 *
73.2x
EV / Sales 2027 * 4.53x
Free-Float
79.01%
Yield 2026 *
-
Yield 2027 * -
07-27 Healios Announces Selection of Akt-01/Hlcn061 Commercial Manufacturing Process for Amed Project CI
04-08 Japan Stocks Rise as US-Iran Ceasefire Eases Geopolitical Concerns MT
04-07 Healios Secures 144 Million Yen Initial Order from Alfresa's Korean Unit for Cosmetic Raw Material MT
04-07 Healios to Supply Stem Cell Culture Material to JENECELL in Cosmetics Deal MT
04-07 Healios K.K. Enters Agreement with Jenecell to Supply Culture Supernatant CI
03-27 Healios K.K. Receives Grant Approval from Ministry of Economy, Trade and Industry for Subsidy Program to Support Capital Investment in Regenerative, Cell, and Gene Therapy Manufacturing Facilities CI
02-20 Healios Plans Capital Reduction to Eliminate Retained Losses MT
02-12 Healios K.K. announced that it has received ¥6.298588125 billion in funding from Athos Capital Limited, New Holland Capital, LLC, Lighthouse Investment Partners, LLC, Walleye Capital LLC CI
02-03 Healios K.K. Announces Start of ARDS Clinical Trial in Japan for the Global Phase 3 REVIVE-ARDS Study CI
01-28 Healios K.K. announced that it expects to receive ¥6.298588125 billion in funding from Athos Capital Limited, New Holland Capital, LLC, Lighthouse Investment Partners, LLC, Walleye Capital LLC CI
01-21 Healios Signs LOI with Alfresa for Ongoing Supply of Stem Cell Culture Supernatant MT
01-20 Healios K.K. Announces Submission of Clinical Trial Notification in Japan for the Global Phase 3 REVIVE-ARDS Study CI
01-20 Healios Submits Japan Trial Plan for Global Phase 3 ARDS Study MT
1 day+2.79%
1 week+10.49%
Current month+2.79%
1 month+25.00%
3 months-11.94%
6 months-32.95%
Current year+7.66%
1 week 278
Extreme 278
309
1 month 232
Extreme 232
309
Current year 208
Extreme 208
483
1 year 208
Extreme 208
628
3 years 114
Extreme 114
747
5 years 114
Extreme 114
2,557
10 years 114
Extreme 114
2,557
Manager TitleAgeSince
Chief Executive Officer 49 2018-02-28
Director of Finance/CFO 49 2019-07-15
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Director/Board Member 49 2012-01-31
Director/Board Member 49 2018-02-28
Director/Board Member 73 2018-02-28
Change 5-day change 1-year change 3-year change Capi.($)
+2.79%+10.49%-45.37%+19.43% 243M
-0.25%-0.92%+49.47%+89.45% 68.13B
+1.21%+2.55%+46.72%+90.66% 63.6B
+1.31%+1.81%+49.04%+12.07% 25.57B
-0.25%-1.92%-16.37%+436.70% 26.6B
+0.33%-10.61%+1.32%-16.27% 25.52B
-6.09%-11.19%+224.80%+351.08% 18.23B
+1.18%+1.66%+35.20%-18.67% 19.69B
-1.49%-6.35%+7.84%+540.26% 15.16B
+4.12%+0.30%+53.01%+150.18% 13.54B
Average +0.23%-2.71%+40.56%+165.49% 27.63B
Weighted average by Cap. +0.12%-2.86%+46.37%+143.45%

Financials

2026 *2027 *
Net sales 541M 3.38M 2.91M 2.74M 2.5M 4.69M 320M 4.72M 32.39M 12.61M 163M 12.68M 12.4M 9.12B 56.96M 49.14M 46.22M 42.11M 79.18M 5.41B 79.61M 546M 213M 2.75B 214M 209M
Net income -4.03B -25.17M -21.71M -20.42M -18.61M -34.99M -2.39B -35.18M -241M -93.97M -1.22B -94.5M -92.45M -1.81B -11.29M -9.74M -9.16M -8.35M -15.69M -1.07B -15.78M -108M -42.15M -545M -42.39M -41.47M
Net Debt -260M -1.62M -1.4M -1.32M -1.2M -2.26M -154M -2.27M -15.57M -6.06M -78.35M -6.09M -5.96M 1.46B 9.14M 7.88M 7.42M 6.76M 12.7M 867M 12.77M 87.67M 34.12M 441M 34.31M 33.57M
Logo Healios K.K.
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Employees
75
Date Price Change Volume
26-09-01 JP¥295.00 +2.79% 2,625,400
26-08-31 JP¥287.00 -6.21% 2,695,000
26-08-28 JP¥306.00 +6.25% 2,454,600
26-08-27 JP¥288.00 +2.13% 1,567,500
26-08-26 JP¥282.00 +1.81% 1,269,700
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
295.00JPY
Average target price
794.83JPY
Spread / Average Target
+169.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4593 Stock